Jeevan Scientific Technology Shows Financial Stability Amidst Market Challenges and Underperformance

Jeevan Scientific Technology, a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation adjustment that reflects its current market standing. The company has demonstrated a strong capacity to manage its debt, evidenced by a low Debt to EBITDA ratio of 1.03 times. This financial stability is complemented by positive results over the last three consecutive quarters, with a notable increase in net sales, which grew by 23.49% to reach Rs 12.51 crore.
Despite these positive indicators, Jeevan Scientific Technology has faced challenges in its performance relative to the benchmark, showing consistent underperformance over the past three years. The stock has generated a return of -12.85% in the last year, which has contributed to its position within a mildly bearish technical range.

The company's return on capital employed (ROCE) stands at 2.6, suggesting an attractive valuation, particularly as it trades at a discount compared to its peers' average historical valuations. The PEG ratio of 0.6 further highlights its valuation metrics in the context of profit growth, which has risen by 124.8% over the past year.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.